MMS Announces Key Executive Appointment to Support Company’s Next Stage of Growth

CANTON, Mich. (8/30/2022) – MMS Holdings Inc. (MMS) – a leading contract research organization (CRO) – announced the appointment of Kelly J. Hill to Chief Strategy Officer. This appointment reflects the company’s accelerating growth as it continues to deliver data-focused clinical research services. A long-time member of MMS’ executive leadership team, Hill brings more than 20…

Read More

CABRI Announces Call for Proposals on Specialized Pro-Resolving Mediator Analytical Methods

The Cayman Biomedical Research Institute (CABRI) is pleased to announce a call for proposals that support essential research on specialized pro-resolving mediator (SPM) analytical methods. There is a critical need for basic research on analytical methods used for specialized pro-resolving mediators (SPMs). SPMs are a family of lipid metabolites derived from polyunsaturated fatty acids (PUFAs)…

Read More

Former Detroit radio voice takes cystic fibrosis fight to Egypt

Original Source   Laura Bonnell had a translator, because the parents in the room were mostly poor, and it’s typically the wealthy in Egypt who speak English. When the screen filled with a picture of her daughters, though — her strong, beautiful, living, 27- and 25-year-old babies — there was no need for words. The universal…

Read More

CRO Announces Expanded Decentralized Clinical Trial Offerings

CANTON, MI (6/7/2022) – MMS Holdings, a data-focused Contract Research Organization (CRO), is pleased to announce a strategic partnership with Medidata, a Dassault Systems company, to provide clients a full range of solutions for clinical data management (CDM) and decentralized clinical trial (DCT) technologies, including Medidata’s unified platform and Rave EDC (Electronic Data Capture). The partnership…

Read More

Novel PTSD Treatment Advances Towards FDA Approval

MMS Holdings (MMS), an award-winning, data-focused contract research organization (CRO), announced today that it has been selected by MAPS Public Benefit Corporation (MAPS PBC) as its contract research organization for the development of a New Drug Application (NDA) for MDMA-assisted therapy for posttraumatic stress disorder (PTSD). This announcement comes on PTSD Awareness day as the confirmatory Phase…

Read More

CRO partners with private equity firm to expand data-focused clinical research services

CANTON, Michigan – June 28, 2022 – MMS Holdings Inc. (“MMS” or the “Company”), a leading data-focused contract research organization (“CRO”), today announced that Lindsay Goldberg, a leading family and founder-focused private equity firm, has completed an investment in the Company alongside MMS Founder and CEO, Dr. Uma Sharma, who will maintain a significant ownership interest.…

Read More

Daicel Arbor Biosciences Expands Leadership and Announces Ravindra Ramadhar as its new President

Ann Arbor, MI (July 1, 2022) – Daicel Arbor Biosciences, a division of Daicel Chiral Technologies, and leader in developing molecular biology research tools, is pleased to introduce Ravindra Ramadhar as its new President. Previously Mr. Ramadhar was Director, Strategy & Business Development within Thermo Fisher Scientific’s Genetics Science Division. Ramadhar brings a vast technical background to Daicel…

Read More

Grand River Aseptic Manufacturing Invests $160 Million with Award from U.S. Government to Support Continued and Future Growth

Grand River Aseptic Manufacturing (“GRAM”), a leading parenteral contract development and manufacturing organization (CDMO), has signed a multi-year contract with the U.S. Department of Health and Human Services and the U.S. Department of Defense. Under the agreement, GRAM will invest $160 million and receive $120 million from the U.S. government to fund the expansions of…

Read More

Gilbert Foundation invests $18M toward Gene Therapy Initiative

Original Source The Gilbert Family Foundation, a private fund established by Dan and Jennifer Gilbert, announced Thursday it is funding more than $18 million in grants toward a cure for Type 1 neurofibromatosis. The money will fund a three-year campaign as part of the organization’s Gene Therapy Initiative. Four grants totaling $4.4 million will be invested…

Read More

U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms

Original Source   Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5…

Read More